Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine.

Autor: Nemunaitis, J¹, Senzer, N¹, Olivares, J², Kumar, P³, Barve, M², Kuhn, J⁴, Nemunaitis, T³, Magee, M⁵, Yu, Y³, Wallraven, G³, Pappen, B O³, Maples, P B³

Publikováno v: Gene Therapy. Sep2013, Vol. 20 Issue 9, p875-879. 5p.

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.

Autor: Rocconi RP; University of Alabama at Birmingham, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mobile, USA., Stanbery L; Gradalis, Inc, Carrollton, USA., Tang M; Stat-Beyond Consulting, Irvine, USA., Madeira da Silva L, Walter A; Gradalis, Inc, Carrollton, USA.; Promedica, Toledo, USA., Monk BJ; Arizona Oncology, (US Oncology Network), University of Arizona, Creighton University, Phoenix, USA., Herzog TJ; University of Cincinnati Cancer Center, Cincinnati, USA., Coleman RL; US Oncology Research, The Woodlands, USA., Manning L; Gradalis, Inc, Carrollton, USA., Wallraven G; Gradalis, Inc, Carrollton, USA., Horvath S; Gradalis, Inc, Carrollton, USA., Bognar E; Gradalis, Inc, Carrollton, USA., Senzer N; Gradalis, Inc, Carrollton, USA., Brun S; Gold Mast Consulting, LLC, Chicago, USA., Nemunaitis J; Gradalis, Inc, Carrollton, USA.

Publikováno v: Communications medicine [Commun Med (Lond)] 2022 Aug 29; Vol. 2, pp. 106. Date of Electronic Publication: 2022 Aug 29 (Print Publication: 2022).

Proof concept for clinical justification of network mapping for personalized cancer therapeutics.

Autor: Nemunaitis, J.^1,2,3 jnemunaitis@mcmrc.com, Senzer, N.^1,2,3, Khalil, I.⁴, Shen, Y.⁵, Kumar, P.⁵, Tong, A.¹, Kuhn, J.³, Lamont, J.³, Nemunaitis, M.¹, Rao, D.⁵, Zhang, Y.-A.⁵, Zhou, Y.⁴, Vorhies, J.¹, Maples, P.⁵, Hill, C.⁴, Shanahan, D.^1,5

Publikováno v: Cancer Gene Therapy. Aug2007, Vol. 14 Issue 8, p686-695. 10p. 3 Color Photographs, 1 Diagram, 1 Chart, 2 Graphs.

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.

Autor: Rocconi RP; University of South Alabama - Mitchell Cancer Institute, Mobile, AL, United States of America., Monk BJ; Arizona Oncology, Phoenix, AZ, United States of America., Walter A; ProMedica, Toledo, OH, United States of America., Herzog TJ; University of Cincinnati Cancer Center, Cincinnati, OH, United States of America., Galanis E; Mayo Clinic, Rochester, MN, United States of America., Manning L; Gradalis, Inc., Carrollton, TX, United States of America., Bognar E; Gradalis, Inc., Carrollton, TX, United States of America., Wallraven G; Gradalis, Inc., Carrollton, TX, United States of America., Stanbery L; Gradalis, Inc., Carrollton, TX, United States of America., Aaron P; Gradalis, Inc., Carrollton, TX, United States of America., Senzer N; Gradalis, Inc., Carrollton, TX, United States of America., Coleman RL; US Oncology Research, The Woodlands, TX, United States of America., Nemunaitis J; Gradalis, Inc., Carrollton, TX, United States of America. Electronic address: jnemunaitis@gradalisinc.com.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2021 Jun; Vol. 161 (3), pp. 676-680. Date of Electronic Publication: 2021 Mar 11.

Exosome-based immunotherapy as an innovative therapeutic approach in melanoma.

Autor: Babaei, Shabnam^1,2 (AUTHOR), Fadaee, Manouchehr^2,3 (AUTHOR), Abbasi-kenarsari, Hajar⁴ (AUTHOR), Shanehbandi, Dariush¹ (AUTHOR), Kazemi, Tohid^1,2 (AUTHOR) Tohid_kazemi@yahoo.com

Publikováno v: Cell Communication & Signaling. 10/31/2024, Vol. 22 Issue 1, p1-20. 20p.